Literature DB >> 2076398

Acute effects of nifedipine versus isosorbide dinitrate on exercise tolerance in patients with isolated coronary artery occlusion and collaterals.

F Barillà1, F Pelliccia, A Valente, C Cianfrocca, F Romeo, A Reale.   

Abstract

The acute effects of slow-release nifedipine and isosorbide dinitrate on exercise tolerance were compared in nine patients with isolated total coronary artery occlusion showing retrograde filling via collaterals. All patients had a reproducible positive exercise stress test off medication before the study. Each patient was randomized to 10 mg slow-release nifedipine and 5 mg isosorbide dinitrate in a single-blind, cross-over study. The exercise stress test was performed 30 minutes after drug administration. After nifedipine, three patients had a negative exercise stress test, whereas the test was negative after isosorbide dinitrate only in one patient. A significantly higher exercise tolerance was detected at peak exercise after nifedipine than after isosorbide dinitrate, as shown by a longer exercise time (380 +/- 44 vs. 295 +/- 41 seconds, p less than 0.001), a more increased maximum work load (355 +/- 89 vs. 255 +/- 55 W x min, p less than 0.02), and a higher rate-pressure product (30,300 +/- 2,500 vs. 26,100 +/- 2,700, p less than 0.01). In conclusion, these results seem to suggest that nifedipine may have a vasomotor effect on collaterals, since it elevated the threshold of ischemia more than isosorbide dinitrate did in patients with isolated coronary artery occlusion, showing retrograde filling via collaterals.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2076398     DOI: 10.1007/BF02018290

Source DB:  PubMed          Journal:  Cardiovasc Drugs Ther        ISSN: 0920-3206            Impact factor:   3.727


  10 in total

Review 1.  The functional value of coronary collaterals in myocardial ischemia and therapeutic approach to enhance collateral flow.

Authors:  M V Cohen
Journal:  Am Heart J       Date:  1978-03       Impact factor: 4.749

2.  Standards for adult exercise testing laboratories. American Heart Association Subcommittee on Rehabilitation, Target Activity Group.

Authors: 
Journal:  Circulation       Date:  1979-02       Impact factor: 29.690

3.  Beneficial enhancement of coronary blood flow by nifedipine. Comparison with nitroglycerin and beta blocking agents.

Authors:  H J Engel; P R Lichtlen
Journal:  Am J Med       Date:  1981-10       Impact factor: 4.965

4.  Difference in nitroglycerin dose-response in the venous and arterial beds.

Authors:  P R Imhof; B Ott; P Frankhauser; L C Chu; J Hodler
Journal:  Eur J Clin Pharmacol       Date:  1980-11       Impact factor: 2.953

5.  Effect of nifedipine on myocardial ischemia: analysis of collateral flow, pulsatile heat and regional muscle shortening.

Authors:  P D Henry; R Shuchleib; R E Clark; J E Perez
Journal:  Am J Cardiol       Date:  1979-10-22       Impact factor: 2.778

6.  The rate-pressure product as an index of myocardial oxygen consumption during exercise in patients with angina pectoris.

Authors:  F L Gobel; L A Norstrom; R R Nelson; C R Jorgensen; Y Wang
Journal:  Circulation       Date:  1978-03       Impact factor: 29.690

7.  Efficacy, duration and mechanism of action of nifedipine in stable exercise-induced angina pectoris.

Authors:  D Ardissino; S De Servi; J A Salerno; G Specchia; M Previtali; A Mussini; P Bobba
Journal:  Eur Heart J       Date:  1983-12       Impact factor: 29.983

8.  Effects of nifedipine on resistance vessels, arteries and veins in man.

Authors:  B F Robinson; R J Dobbs; C R Kelsey
Journal:  Br J Clin Pharmacol       Date:  1980-11       Impact factor: 4.335

9.  Relation of antianginal efficacy of nifedipine to degree of coronary arterial narrowing and to presence of coronary collateral vessels.

Authors:  W Schulz; S Jost; G Kober; M Kaltenbach
Journal:  Am J Cardiol       Date:  1985-01-01       Impact factor: 2.778

10.  Comparison of two dihydropyridine calcium antagonists on coronary collateral blood flow in acute myocardial ischemia.

Authors:  S R Jolly; H F Hardman; G J Gross
Journal:  J Pharmacol Exp Ther       Date:  1981-04       Impact factor: 4.030

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.